Table I.

The effect of anti-CTLA-4 mAb 10D1 on T lymphocyte populations in monkeysa

T Cell MarkerGroup (n = 6)PreDay 1Day 29Day 57Day 141
CD3+/CD4+/CD25+Vaccine only3.8 ± 2.3b6.4 ± 3.56.2 ± 4.52.3 ± 2.94.0 ± 2.6
Vaccine with 10D19.1 ± 0.89.2 ± 1.110.3 ± 1.58.3 ± 2.17.7 ± 2.6
CD3+/CD8+/CD25+Vaccine only8.9 ± 2.510.6 ± 2.810.7 ± 3.36.2 ± 1.75.5 ± 2.2
Vaccine with 10D16.7 ± 1.38.4 ± 1.38.5 ± 2.06.6 ± 1.06.0 ± 2.2
CD3+/CD4+/CD69+Vaccine only7.3 ± 4.69.2 ± 3.811.9 ± 7.24.7 ± 1.312.2 ± 11.6
Vaccine with 10D16.0 ± 3.47.0 ± 2.37.4 ± 3.74.4 ± 3.811.4 ± 4.2
CD3+/CD8+/CD69+Vaccine only12.9 ± 8.415.9 ± 10.813.9 ± 6.611.5 ± 7.719.5 ± 10.2
Vaccine with 10D113.3 ± 5.213.8 ± 5.212.7 ± 6.811.4 ± 6.518.2 ± 5.8
CD3+/CD4+/HLA-DR+Vaccine only1.1 ± 1.80.5 ± 0.51.1 ± 0.60.6 ± 0.40.5 ± 0.6
Vaccine with 10D10.9 ± 0.30.3 ± 0.30.4 ± 0.60.3 ± 0.50.4 ± 0.6
CD3+/CD8+/HLA-DR+Vaccine only1.8 ± 1.01.2 ± 0.71.2 ± 0.91.5 ± 1.00.6 ± 0.6
Vaccine with 10D11.3 ± 1.00.6 ± 0.70.9 ± 0.70.9 ± 0.50.7 ± 0.5
  • a Flow cytometric analysis of surface expression of T cell markers.

  • b Values represent the percent positive cells (based on total lymphocyte gate) expressed as the mean percent ± SD.